MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2023.06.041

Медицинская библиотека · JACC. Cardiovascular interventions · 2023

5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results.

Guerrero Mayra E, Eleid Mackram F, Wang Dee Dee, Pursnani Amit, Kodali Susheel K, George Isaac, Palacios Igor, Russell Hyde, Makkar Raj R, Kar Saibal, Satler Lowell F, Rajagopal Vivek, Dangas George, Tang Gilbert H L, McCabe James M, Whisenant Brian K, Fang Kenith, Balan Prakash, Smalling Richard, Kaptzan Tatiana, Lewis Bradley, Douglas Pamela S, Hahn Rebecca T, Thaden Jeremy, Oh Jae K, Leon Martin, O'Neill William, Rihal Charanjit

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective trial to evaluate the safety and feasibility of balloon-expandable aortic transcatheter heart valves in patients with failed surgical bioprostheses or annuloplasty rings and severe mitral annular calcification treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral annular calcification (ViMAC).

OBJECTIVES

The aim of this study was to evaluate 5-year outcomes among these patients.

METHODS

A multicenter prospective study was conducted among patients at high surgical risk at 13 U.S. sites. Patients underwent MViV (n = 30), MViR (n = 30), or ViMAC (n = 31) and were followed annually for 5 years. Kansas City Cardiomyopathy Questionnaire scores were obtained at baseline and follow-up visits. Echocardiograms were analyzed at independent core laboratories.

RESULTS

A total of 91 patients underwent transcatheter mitral valve replacement (February 2015 to December 2017). The mean age was 74.3 ± 8.9 years. At 5-year follow-up, the lowest all-cause mortality was observed in the MViV group (21.4%), 94.7% of patients were in NYHA functional class I or II, and the mean mitral gradient was 6.6 ± 2.5 mm Hg. The MViR and ViMAC groups had higher all-cause mortality (65.5% and 67.9%), most survivors were in NYHA functional classes I and II (50% and 55.6%), and mean mitral gradients remained stable (5.8 ± 0.1 and 6.7 ± 2.5 mm Hg). Significant improvements in Kansas City Cardiomyopathy Questionnaire scores were observed when all 3 arms were pooled.

CONCLUSIONS

MViV, MViR, and ViMAC procedures were associated with sustained improvement of heart failure symptoms and quality of life among survivors at 5 years. Transcatheter heart valve function remained stable in all 3 groups. Patients treated with MViV had excellent survival at 5 years, whereas survival was lower in the MViR and ViMAC groups, consistent with underlying disease severity. Patients with more residual mitral regurgitation had higher mortality.

Для цитирования: Guerrero Mayra E, Eleid Mackram F, Wang Dee Dee, Pursnani Amit, Kodali Susheel K, George Isaac, Palacios Igor, Russell Hyde, Makkar Raj R, Kar Saibal, Satler Lowell F, Rajagopal Vivek, Dangas George, Tang Gilbert H L, McCabe James M, Whisenant Brian K, Fang Kenith, Balan Prakash, Smalling Richard, Kaptzan Tatiana, Lewis Bradley, Douglas Pamela S, Hahn Rebecca T, Thaden Jeremy, Oh Jae K, Leon Martin, O'Neill William, Rihal Charanjit. 5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results.. JACC. Cardiovascular interventions. 2023. DOI: 10.1016/j.jcin.2023.06.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.